Other candidates target antigens for HCC TCR-T therapy involve GPC3 (99), New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (100), and human telomerase reverse transcriptase (hTERT) (101). The gene discussed is GPC3; the disease is hepatocellular carcinoma.